Bukwang Pharm (003000) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.018x

Based on the latest financial reports, Bukwang Pharm (003000) has a cash flow conversion efficiency ratio of -0.018x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-6.24 Billion ≈ $-4.23 Million USD) by net assets (₩340.83 Billion ≈ $230.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Bukwang Pharm - Cash Flow Conversion Efficiency Trend (2007–2024)

This chart illustrates how Bukwang Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Bukwang Pharm debt and liabilities for a breakdown of total debt and financial obligations.

Bukwang Pharm Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Bukwang Pharm ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Shandong Hongyu Agricultural Machinery Co Ltd
SHE:002890
-0.003x
Caleres Inc
NYSE:CAL
0.065x
Goodwill E Health Info Co Ltd
SHG:688246
-0.006x
Teck Resources Limited
F:TPT
0.025x
Norma Group AG NA O.N.
XETRA:NOEJ
0.035x
IGG Inc
F:I91
-0.006x
AS Tallink Grupp
HE:TALLINK
0.086x
Lontrue Co Ltd
SHE:300175
-0.107x

Annual Cash Flow Conversion Efficiency for Bukwang Pharm (2007–2024)

The table below shows the annual cash flow conversion efficiency of Bukwang Pharm from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Bukwang Pharm.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩244.15 Billion
≈ $165.45 Million
₩34.36 Billion
≈ $23.29 Million
0.141x +452.19%
2023-12-31 ₩234.26 Billion
≈ $158.76 Million
₩-9.36 Billion
≈ $-6.34 Million
-0.040x -165.99%
2022-12-31 ₩271.85 Billion
≈ $184.23 Million
₩16.46 Billion
≈ $11.16 Million
0.061x -36.06%
2021-12-31 ₩280.06 Billion
≈ $189.79 Million
₩26.52 Billion
≈ $17.98 Million
0.095x +3451.72%
2020-12-31 ₩271.19 Billion
≈ $183.78 Million
₩723.17 Million
≈ $490.08K
0.003x +103.72%
2019-12-31 ₩326.49 Billion
≈ $221.25 Million
₩-23.41 Billion
≈ $-15.86 Million
-0.072x -534.85%
2018-12-31 ₩413.44 Billion
≈ $280.18 Million
₩6.82 Billion
≈ $4.62 Million
0.016x -59.31%
2017-12-31 ₩211.30 Billion
≈ $143.20 Million
₩8.56 Billion
≈ $5.80 Million
0.041x +212.04%
2016-12-31 ₩214.63 Billion
≈ $145.45 Million
₩-7.76 Billion
≈ $-5.26 Million
-0.036x -179.08%
2015-12-31 ₩225.15 Billion
≈ $152.58 Million
₩10.30 Billion
≈ $6.98 Million
0.046x -65.53%
2014-12-31 ₩210.00 Billion
≈ $142.31 Million
₩27.86 Billion
≈ $18.88 Million
0.133x -26.94%
2013-12-31 ₩201.07 Billion
≈ $136.26 Million
₩36.52 Billion
≈ $24.75 Million
0.182x +11.16%
2007-12-31 ₩170.63 Billion
≈ $115.63 Million
₩27.87 Billion
≈ $18.89 Million
0.163x --

About Bukwang Pharm

KO:003000 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$422.58 Million
₩623.56 Billion KRW
Market Cap Rank
#13412 Global
#449 in Korea
Share Price
₩6320.00
Change (1 day)
-3.95%
52-Week Range
₩3225.00 - ₩9600.00
All Time High
₩36947.85
About

Bukwang Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products in South Korea and internationally. It offers its products in oral solid dosage forms, injections, oral solutions, external solutions, and ointments. The company also provides ethical drugs, including drugs for treating diabetic peripheral neuropathy, hypothyroidism, toxic liver disease, chronic hepatitis, live… Read more